NCT01134159已完成不适用
Registry Experience at the WAshington Hospital CenteR, DeS - Taxus Liberte vs Xience V
Medstar Health Research Institute10 个研究点 分布在 1 个国家目标入组 1,200 人开始时间: 2010年6月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,200
- 试验地点
- 10
- 主要终点
- Major adverse cardiac events,
研究概览
简要总结
Multicenter, retrospective registry to collect 9-12 month follow-up data to evaluate major adverse cardiac events in patients whom have undergone percutaneous coronary intervention and received either Taxus Liberte or Xience V.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients 18 years of age or older, both genders
- •Underwent PCI with Taxus Liberte (alone) or Xience (alone)
排除标准
- •Underwent PCI with a non-Taxus Liberte or Xience V DES during the same procedure
- •Received both Taxus-Liberte and Xience-V during the same index procedure
- •Patients not taking, or unable to take, dual antiplatelet therapy (aspirin plus clopidogrel or prasugrel).
结局指标
主要结局
Major adverse cardiac events,
时间窗: 1 year
A composite of all-cause death, Q-wave myocardial infarction, and target vessel revascularization
次要结局
- Stent thrombosis(1 year)
- Target vessel revascularization(1 year)
- Cardiac death(1 year)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
不适用
REWARDS Premier Taxus-Liberte vs Xience VCoronary Artery DiseaseNCT02256527Medstar Health Research Institute917
已完成
不适用
Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney DiseaseChronic Kidney DiseaseNCT02492672American Regent, Inc.50
招募中
不适用
Observation of Clinical Routine Care for Patients With BIOTRONIK Implantable Cardiac Monitors (ICMs)TachycardiaBradycardiaCryptogenic StrokeAtrial FibrillationSyncopeNCT04075084Biotronik SE & Co. KG1,400
招募中
不适用
Prospective Registry to Evaluate Outcomes of NanoBone® Bone Graft in Acute TraumaFractures, BoneNCT06256458Artoss Inc.200
终止
不适用
An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG®Myeloid Leukemia, Chronic-Phase, Accelerated-Phase, Blast-Phase, Ph+ALLNCT02455024Ariad Pharmaceuticals3